The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
+ Phase 2 sample size and duration Global Phase 3 trials (obesity, diabetes and older-adult cohorts) begin enrolling in the second half of 2025 to confirm durability (longer dosing protocol and follow up) and capture rare adverse events (larger sample size, higher statistical power).
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.